Targeting angiopoietin-2 signaling in cancer therapy

Bibliography

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182–6
   PubMed Web of Science ®Google Scholar
• Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007;5(7):655–65
   PubMed Web of Science ®Google Scholar
• Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13(9):1055–66
   PubMed Web of Science ®Google Scholar
• Tammela T, Petrova TV, Alitalo K. Molecular lymphangiogenesis: new players. Trends Cell Biol 2005;15(8):434–41
   PubMed Web of Science ®Google Scholar
• Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10(3):165–77
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322):55–60
   PubMed Web of Science ®Google Scholar
• Machein MR, Knedla A, Knoth R, et al. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 2004;165(5):1557–70
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249–57
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284(5422):1994–8
   PubMed Web of Science ®Google Scholar
• Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;99(17):11205–10
   PubMed Web of Science ®Google Scholar
• Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009;29(8):2011–22
   PubMed Web of Science ®Google Scholar
• Imanishi Y, Hu B, Xiao G, et al. Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the Integrin-linked Kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway. J Biol Chem 2011;286(33):29249–60
   PubMed Web of Science ®Google Scholar
• Zhang J, Fukuhara S, Sako K, et al. Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of beta-catenin. J Biol Chem 2011;286(10):8055–66
   PubMed Web of Science ®Google Scholar
• Felcht M, Luck R, Schering A, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 2012;122(6):1991–2005
   PubMed Web of Science ®Google Scholar
• Etoh T, Inoue H, Tanaka S, et al. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001;61(5):2145–53
   PubMed Web of Science ®Google Scholar
• Sfiligoi C, de Luca A, Cascone I, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003;103(4):466–74
   PubMed Web of Science ®Google Scholar
• Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004;204(1):1–10
   PubMed Web of Science ®Google Scholar
• Pomyje J, Zivny JH, Stopka T, et al. Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma. Melanoma Res 2001;11(6):639–43
   PubMed Web of Science ®Google Scholar
• Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155(6):1967–76
   PubMed Web of Science ®Google Scholar
• Ding H, Roncari L, Wu X, et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro Oncol 2001;3(1):1–10
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Dancey G, Hackshaw A, et al. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr Relat Cancer 2009;16(3):967–76
   PubMed Web of Science ®Google Scholar
• Wong MP, Chan SY, Fu KH, et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 2000;29(1):11–22
   PubMed Web of Science ®Google Scholar
• Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010;9(10):2641–51
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6(5):507–16
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27(21):3557–65
   PubMed Web of Science ®Google Scholar
• Doi T, Ohtsu A, Fuse N, et al. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;71(1):227–35
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6(6):327–38
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Miki C, Toiyama Y, et al. Serum level of soluble vascular cell adhesion molecule 1 is a valuable prognostic marker in colorectal carcinoma. Dis Colon Rectum 2009;52(7):1330–6
   PubMed Web of Science ®Google Scholar
• Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010;16(11):3044–56
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23(31):8136–9
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7(5):575–83
   PubMed Web of Science ®Google Scholar
• Hata K, Udagawa J, Fujiwaki R, et al. Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 2002;62(4):340–8
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484–96
   PubMed Web of Science ®Google Scholar
• Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30(4):362–71
   PubMed Web of Science ®Google Scholar
• Lu JF, Rasmussen E, Karlan BY, et al. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol 2012;69(5):1135–44
   PubMed Web of Science ®Google Scholar
• Vergote IB, Benzaquen AO, Baurain J, et al. A Phase 1B study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery. Ann Oncol 2012;23(Suppl 9):ix319–ix33
   Google Scholar
• NCT01493505: TRINOVA-3: a Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01493505 [Cited 21 November 2012]
   Google Scholar
• NCT01204749: TRINOVA-1: a Study of AMG 386 or Placebo, in Combination with weekly Paclitaxel chemotherapy, as treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01204749 [Cited 21 November 2012]
   Google Scholar
• NCT01281254: TRINOVA-2: A phase 3, randomized, double-blind trial of Pegylated Liposomal Doxorubicin (PLD) plus AMG 386 or placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01281254 [Cited 21 November 2012]
   Google Scholar
• Rini B, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney : a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012;
   Google Scholar
• Atkins MB, Ravaud A, Gwenaelle G, et al. Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study. J Clin Oncol 2012;30(Suppl 4606):abstract
   Google Scholar
• NCT01664182: a randomized phase 2 study of AMG 386 With or Without Continued Anti-Vascular Endothelial Growth Factor (VEGF) therapy in patients with renal cell carcinoma who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01664182 [Cited 22 November 2012]
   Google Scholar
• Eatock MM, Tebbutt NC, Bampton CL, et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 2012;24(3):710–18
   PubMed Web of Science ®Google Scholar
• Peeters M, Strickland AH, Lichinitser M, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108(3):503–11
   PubMed Web of Science ®Google Scholar
• NCT01249521: open Label Phase II Study Evaluating the Combination of Bevacizumab and AMG386 Without Chemotherapy as First Line Treatment of Advanced Colorectal Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01249521 [Cited January 2013]
   Google Scholar
• Niu G, Carter WB. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007;67(4):1487–93
   Google Scholar
• Wildiers HG, Goncalves A, Kemeny M, et al. Phase Ib study of open-label AMG 386 plus paclitaxel (P) and trastuzumab (T) or capecitabine (C) and lapatinib (L) in patients (pts) with HER2+ locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012;30
   Google Scholar
• Dieras VJ, Jassem J, Dirix LY, et al.A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). J Clin Oncol 2011;29(Suppl):abstract 544
   Google Scholar
• NCT00872014: phase 2 open-label multi-center study to evaluate the efficacy and safety of AMG 386 and Sorafenib as first line therapy for subjects with advanced or inoperable hepatocellular carcinoma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00872014 [Cited 22 November 2012]
   Google Scholar
• NCT01553188: a phase II Study of AMG 386 and abiraterone in metastatic castration resistant prostate cancer. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01553188 [Cited 22 November 2012]
   Google Scholar
• NCT01666977: a phase 1b/2 Trial of AMG 386 in combination with pemetrexed and carboplatin as first line treatment of metastatic non-squamous non-small cell lung cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01666977 [Cited 22 November 2012]
   Google Scholar
• NCT01623869: Phase II Study of the angiopoietin-1 and -2 peptibody AMG 386 for the treatment of angiosarcoma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01623869 [Cited 22 November 2012]
   Google Scholar
• NCT01290263: Phase I/II study of amgen 386 with and without bevacizumab for recurrent glioblastoma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01290263 [Cited 22 November 2012]
   Google Scholar
• NCT01609790: phase II double-blinded placebo-controlled study of bevacizumab with or without AMG 386 in patients with recurrent Glioblastoma or gliosarcoma. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01609790 [Cited 22 November 2012]
   Google Scholar
• NCT01555268: trebananib with or without low-dose cytarabine in treating patients with acute myeloid leukemia. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01555268 [Cited 22 November 2012]
   Google Scholar
• Leow CC, Coffman K, Inigo I, et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 2012;40(5):1321–30
   PubMed Web of Science ®Google Scholar
• Holopainen T, Saharinen P, D'Amico G, et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 2012;104(6):461–75
   PubMed Web of Science ®Google Scholar
• Molnar N, Siemann DW. Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. Microvasc Res 2012;83(3):290–7
   PubMed Web of Science ®Google Scholar
• Natale RB, Rizvi NA, Infante JR, et al. Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. ASCO Meeting Abstracts 2012;30(15_Suppl):TPS2621
   Google Scholar
• NCT01137552: A phase 1 dose escalation study of AMG 780 in adult subjects with advanced solid tumor. Available from: http://www.clinicaltrials.gov [Last accessed 13 November 2012]
   Google Scholar
• Papadopoulos KP, Chau NG, Patnaik A, et al. Daly C, et al. A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. ASCO Meeting Abstracts 2011;29(15_Suppl):TPS159
   Google Scholar
• Daly C, Eichten A, Castanaro C, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013;73(1):108–18
   PubMed Web of Science ®Google Scholar
• NCT01688960: a phase 1b Study of combined angiogenesis inhibition by administering REGN910 and aflibercept (Ziv-aflibercept) in patients with advanced solid malignancies. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01688960
   Google Scholar
• Huang H, Lai JY, Do J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011;17(5):1001–11
   PubMed Web of Science ®Google Scholar
• Rosen LS, Mendelson DS, Cohen RB, et al. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 2010;28(Suppl):2524
   Google Scholar
• Lee S, Rosen DSM, Michael S, et al. Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal. CovX body inhibiting angiopoietin 2 (Ang-2), with sunitinib. J Clin Oncol 2012;30(Suppl):abstract 3032
   Google Scholar
• NCT01441414: a Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Inhibitor In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01441414?term=cvx-060&rank=4 [Cited 25 November 2012]
   Google Scholar
• Mendelson DS, Rosen LS, Gordon MS, et al. First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor. J Clin Oncol 2011;29(Suppl):abstract 3055
   Google Scholar
• NCT01004822: A phase 1, multicenter, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study Of CVX-241, A Selective angiopoietin-2 and vascular endothelial growth factor binding, anti-angiogenic COVX-body, in patients with advanced solid tumors. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01004822?term=CVX-241&rank=1 [Cited 25 November 2012]
   Google Scholar
• Thomas M, Kienast Y, Scheuer W, et al. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to pan-angiopoietin-1/-2 inhibitors. PLoS One 2013;8(2):e54923
   PubMed Web of Science ®Google Scholar
• Popkov M, Jendreyko N, McGavern DB, et al. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res 2005;65(3):972–81
   PubMed Web of Science ®Google Scholar
• Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007;109(12):5276–85
   PubMed Web of Science ®Google Scholar
• De Palma M, Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin Cancer Res 2011;17(16):5226–32
   PubMed Web of Science ®Google Scholar
• Hudkins RL, Becknell NC, Zulli AL, et al. Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent. J Med Chem 2011;55(2):903–13
   Web of Science ®Google Scholar
• NCT00875264: an open-label study to determine the maximum tolerated oral dose of the kinase inhibitor CEP-11981 in patients with advanced cancer. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00875264?term=CEP-11981&rank=1
   Google Scholar
• Komrokji RS, List AF, Khoury HJ, et al. Phase 1 dose-escalation/expansion study of the p38/Tie2 inhibitor ARRY-614 in patients with IPSS low/Int-1 risk myelodysplastic syndromes. ASH Annual Meeting Abstracts 2011;118(21):118
   Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303–12
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295–302
   PubMed Web of Science ®Google Scholar
• Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012;13(10):1055–62
   PubMed Web of Science ®Google Scholar
• Kies MS, Blumenschein GR Jr, Christensen O. Christensen et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC) [abstract 7585]. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• NCT01003015: an uncontrolled open label multicenter phase II SAFETY study of BAY73-4506 in patients with Hepatocellular Carcinoma (HCC). Available from: http://clinicaltrials.gov/ct2/show/NCT01003015 [Cited 19 December 2012]
   Google Scholar
• Besterman JM, Fournel M, Dupont I, et al. Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib. J Clin Oncol 2010;28(Suppl):abstract e13595
   Google Scholar
• O'Dwyer PJ, Papadopoulos KP, Tolcher AW, et al. MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: phase I clinical experience. J Clin Oncol 2011;29(Suppl); abstract 3083
   Google Scholar
• NCT00975767: a phase I/II study of MGCD265 in combination with erlotinib or docetaxel in subjects with advanced malignancies and in subjects with advanced non-small cell lung cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00975767 [Cited 19 December 2012]
   Google Scholar
• Chae S-S, Kamoun WS, Farrar CT, et al. Angiopoietin-2 interferes with anti-VEGFR2–induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16(14):3618–27
   PubMed Web of Science ®Google Scholar
• Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010;70(6):2213–23
   PubMed Web of Science ®Google Scholar
• Brown JL, Cao ZA, Pinzon-Ortiz M, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9(1):145–56
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bahner M, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 2011;108(27):11187–92
   PubMed Web of Science ®Google Scholar
• Koh YJ, Kim HZ, Hwang SI, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010;18(2):171–84
   PubMed Web of Science ®Google Scholar
• Jendreyko N, Popkov M, Rader C, Barbas CF. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA 2005;102(23):8293–8
   PubMed Web of Science ®Google Scholar
• Park JH, Park KJ, Kim YS, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007;132(1):200–6
   PubMed Web of Science ®Google Scholar
• Scholz A, Rehm VA, Rieke S, et al. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 2007;102(11):2471–81
   PubMed Web of Science ®Google Scholar
• Matsubara T, Kanto T, Kuroda S, et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlated with angiogenesis. Hepatology 2013;57(4):1416–25
   PubMed Web of Science ®Google Scholar
• Sie M, Wagemakers M, Molema G, et al. The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neurosurg 2009;110(1):147–55
   PubMed Web of Science ®Google Scholar
• Helfrich I, Edler L, Sucker A, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009;15(4):1384–92
   PubMed Web of Science ®Google Scholar
• Szarvas T, Jager T, Totsch M, et al. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 2008;14(24):8253–62
   PubMed Web of Science ®Google Scholar
• Wang J, Wu K, Zhang D, et al. Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun 2005;337(1):386–93
   PubMed Web of Science ®Google Scholar
• Bullock AJ, Zhang A, O'Neill A, et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC) [Abstract]. J Clin Oncol 2010;28:4630
   PubMedGoogle Scholar
• Schliemann C, Bieker R, Thoennissen N, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007;21(9):1901–6
   PubMed Web of Science ®Google Scholar
• Maffei R, Martinelli S, Santachiara R, et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 2010;116(4):584–92
   PubMed Web of Science ®Google Scholar
• Anargyrou K, Terpos E, Vassilakopoulos TP, et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 2008;93(3):451–4
   PubMed Web of Science ®Google Scholar
• Bhaskar A, Gupta R, Sreenivas V, et al. Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk Res 2013;37(4):410–15
   PubMed Web of Science ®Google Scholar
• NCT01538095: a phase 1 study of AMG 386, an angiopoietin neutralizing peptibody, in children with relapsed or refractory solid tumors, including CNS tumors. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01538095
   Google Scholar
• NCT01548482: A phase I trial of AMG 386 and temsirolimus in advanced solid tumors with an expansion cohort in uterine cancer, renal cell carcinoma and carcinoid tumors. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01548482 [Cited 16 December 2012]
   Google Scholar